KR20230008801A - Sars-cov-2 항원을 암호화하는 최적화된 뉴클레오티드 서열 - Google Patents

Sars-cov-2 항원을 암호화하는 최적화된 뉴클레오티드 서열 Download PDF

Info

Publication number
KR20230008801A
KR20230008801A KR1020227042785A KR20227042785A KR20230008801A KR 20230008801 A KR20230008801 A KR 20230008801A KR 1020227042785 A KR1020227042785 A KR 1020227042785A KR 20227042785 A KR20227042785 A KR 20227042785A KR 20230008801 A KR20230008801 A KR 20230008801A
Authority
KR
South Korea
Prior art keywords
seq
cov
sars
protein
nucleotide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227042785A
Other languages
English (en)
Korean (ko)
Inventor
아누샤 디아스
캉 앤 트랜
민니 자차리아
샤오보 구
리안 뵈글린
조셉 에이. 스케일스키
쉬리랑 카르브
프랑크 데로사
통-밍 푸
키릴 칼닌
수드하 치부쿨라
티모시 플리트니크
다닐로 카시미로
제프리 에스. 두빈스
Original Assignee
트랜슬레이트 바이오 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 트랜슬레이트 바이오 인코포레이티드 filed Critical 트랜슬레이트 바이오 인코포레이티드
Publication of KR20230008801A publication Critical patent/KR20230008801A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
KR1020227042785A 2020-05-07 2021-05-07 Sars-cov-2 항원을 암호화하는 최적화된 뉴클레오티드 서열 Ceased KR20230008801A (ko)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US202063021319P 2020-05-07 2020-05-07
US63/021,319 2020-05-07
US202063032825P 2020-06-01 2020-06-01
US63/032,825 2020-06-01
US202063076718P 2020-09-10 2020-09-10
US202063076729P 2020-09-10 2020-09-10
US63/076,718 2020-09-10
US63/076,729 2020-09-10
US202063088739P 2020-10-07 2020-10-07
US63/088,739 2020-10-07
US202163143612P 2021-01-29 2021-01-29
US202163143604P 2021-01-29 2021-01-29
US63/143,612 2021-01-29
US63/143,604 2021-01-29
US202163146807P 2021-02-08 2021-02-08
US63/146,807 2021-02-08
PCT/US2021/031256 WO2021226436A1 (en) 2020-05-07 2021-05-07 Optimized nucleotide sequences encoding sars-cov-2 antigens

Publications (1)

Publication Number Publication Date
KR20230008801A true KR20230008801A (ko) 2023-01-16

Family

ID=78468438

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227042785A Ceased KR20230008801A (ko) 2020-05-07 2021-05-07 Sars-cov-2 항원을 암호화하는 최적화된 뉴클레오티드 서열

Country Status (8)

Country Link
US (1) US20240342269A1 (cg-RX-API-DMAC7.html)
EP (1) EP4146265A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023524767A (cg-RX-API-DMAC7.html)
KR (1) KR20230008801A (cg-RX-API-DMAC7.html)
AU (1) AU2021269042A1 (cg-RX-API-DMAC7.html)
CA (1) CA3177940A1 (cg-RX-API-DMAC7.html)
IL (1) IL297962A (cg-RX-API-DMAC7.html)
WO (1) WO2021226436A1 (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE20164728T1 (de) 2015-10-22 2021-09-30 Modernatx, Inc. Impfstoffe gegen atemwegsvirus
CA3146369A1 (en) 2019-07-08 2021-01-14 Translate Bio, Inc. Improved mrna-loaded lipid nanoparticles and processes of making the same
CN118490818A (zh) 2020-04-22 2024-08-16 生物技术欧洲股份公司 冠状病毒疫苗
WO2021249011A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Hiv vaccine compositions, methods, and uses thereof
WO2021249116A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Coronavirus vaccine compositions, methods, and uses thereof
EP4205761A4 (en) * 2020-08-27 2024-05-29 Cellid Co., Ltd NOVEL RECOMBINANT CORONAVIRUS SPIKE PROTEIN, POLYNUCLEOTIDE, VECTOR WITH POLYNUCLEOTIDE AND VACCINE FOR PREVENTING OR TREATING CORONAVIRUS INFECTION WITH VECTOR
WO2022041760A1 (en) 2020-08-31 2022-03-03 Sichuan Clover Biopharmaceuticals, Inc. Methods and compositions for purification of trimeric fusion proteins
WO2022099003A1 (en) * 2020-11-06 2022-05-12 Sanofi Lipid nanoparticles for delivering mrna vaccines
AU2022207495A1 (en) * 2021-01-15 2023-08-03 Modernatx, Inc. Variant strain-based coronavirus vaccines
US20240100151A1 (en) * 2021-01-15 2024-03-28 Moderna TX, Inc. Variant strain-based coronavirus vaccines
US12397051B2 (en) * 2021-09-14 2025-08-26 Globe Biotech Limited Vaccine for use against coronavirus and variants thereof
EP4183409A1 (en) * 2021-11-17 2023-05-24 Charité - Universitätsmedizin Berlin Vaccine with improved immunogenicity against mutant coronaviruses
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
WO2023094713A2 (en) * 2021-11-29 2023-06-01 BioNTech SE Coronavirus vaccine
WO2023098842A1 (en) * 2021-12-03 2023-06-08 Suzhou Abogen Biosciences Co., Ltd. NUCLEIC ACID VACCINES FOR CORONAVIRUS BASED ON SEQUENCES DERIVED FROM SARS-CoV-2 OMICRON STRAIN
CA3242439A1 (en) 2021-12-17 2023-06-22 Sanofi Lyme disease rna vaccine
WO2023145874A1 (ja) * 2022-01-28 2023-08-03 国立研究開発法人医薬基盤・健康・栄養研究所 コロナウイルスに対する新規なモノクローナル抗体
CN116731192A (zh) * 2022-03-01 2023-09-12 上海泽润生物科技有限公司 重组刺突蛋白及其制备方法和用途
CN116768988A (zh) * 2022-03-09 2023-09-19 中生复诺健生物科技(上海)有限公司 编码新型冠状病毒S蛋白的mRNA疫苗
CN116768987A (zh) * 2022-03-09 2023-09-19 中生复诺健生物科技(上海)有限公司 编码新型冠状病毒S蛋白的mRNA疫苗
CN114404584B (zh) * 2022-04-01 2022-07-26 康希诺生物股份公司 一种新型冠状病毒mRNA疫苗及其制备方法和用途
WO2023214082A2 (en) 2022-05-06 2023-11-09 Sanofi Signal sequences for nucleic acid vaccines
DE102023002588A1 (de) * 2022-06-26 2024-01-25 BioNTech SE Coronavirus-Impfstoff
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
JP2025536595A (ja) 2022-11-04 2025-11-07 サノフィ パスツール インコーポレイテッド メッセンジャーrnaテール付加の方法
WO2024157279A1 (en) * 2023-01-23 2024-08-02 Indian Institute Of Science Stabilized immunogens derived from spike of coronavirus, compositions and methods thereof
WO2024196683A2 (en) * 2023-03-17 2024-09-26 Research Institute At Nationwide Children's Hospital Vsv-based sars-cov-2 vaccine candidates and igy antibodies as prophylactic and therapeutic agents against sars-cov-2 and variants of concern
WO2024238911A1 (en) * 2023-05-17 2024-11-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant murine pneumonia virus expressing severe acute respiratory syndrome coronavirus 2 (sars-cov-2) spike protein
WO2025106792A1 (en) * 2023-11-15 2025-05-22 La Jolla Institute For Immunology Prefusion-stabilized sars-cov-2 spike s2 subunit as antigen for broad pan-coronavirus vaccines
CN117482240B (zh) * 2024-01-03 2024-04-26 深圳大学总医院 一种rna疫苗递送制剂及其制备方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
FR2645866B1 (fr) 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5744335A (en) 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
CA2569664C (en) 2004-06-07 2013-07-16 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
PL2578685T3 (pl) 2005-08-23 2020-01-31 The Trustees Of The University Of Pennsylvania Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania
AU2009303345B2 (en) 2008-10-09 2015-08-20 Arbutus Biopharma Corporation Improved amino lipids and methods for the delivery of nucleic acids
WO2010053572A2 (en) 2008-11-07 2010-05-14 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
KR20220038506A (ko) 2009-06-10 2022-03-28 알닐람 파마슈티칼스 인코포레이티드 향상된 지질 조성물
EA022786B1 (ru) 2009-07-31 2016-03-31 Этрис Гмбх Рнк с комбинацией из немодифицированных и модифицированных нуклеотидов для экспрессии белков
SI2506857T1 (en) 2009-12-01 2018-08-31 Translate Bio, Inc. Delivery of mRNA for the enrichment of proteins and enzymes in human genetic diseases
EP4074693A1 (en) 2011-06-08 2022-10-19 Translate Bio, Inc. Cleavable lipids
US9512073B2 (en) 2011-10-27 2016-12-06 Massachusetts Institute Of Technology Amino acid-, peptide-and polypeptide-lipids, isomers, compositions, and uses thereof
BR112014024131A2 (pt) 2012-03-29 2017-07-25 Shire Human Genetic Therapies lipídios catiônicos ionizáveis
EA201591229A1 (ru) 2013-03-14 2016-01-29 Шир Хьюман Дженетик Терапис, Инк. Способы очистки матричной рнк
EA201591283A1 (ru) 2013-03-14 2016-02-29 Шир Хьюман Дженетик Терапис, Инк. Количественная оценка эффективности кэп матричной рнк
AU2014340149B2 (en) * 2013-10-22 2020-12-24 Shire Human Genetic Therapies, Inc. CNS delivery of mRNA and uses thereof
US10059655B2 (en) 2013-12-19 2018-08-28 Novartis Ag Lipids and lipid compositions for the delivery of active agents
EP4729528A3 (en) 2014-04-25 2026-06-24 Translate Bio, Inc. Methods for purification of messenger rna
WO2015184256A2 (en) 2014-05-30 2015-12-03 Shire Human Genetic Therapies, Inc. Biodegradable lipids for delivery of nucleic acids
CA2953341C (en) 2014-06-25 2023-01-24 Acuitas Therapeutics Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2016004318A1 (en) 2014-07-02 2016-01-07 Shire Human Genetic Therapies, Inc. Encapsulation of messenger rna
WO2016004202A1 (en) 2014-07-02 2016-01-07 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
WO2016118724A1 (en) 2015-01-21 2016-07-28 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
EP3247398A4 (en) 2015-01-23 2018-09-26 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
RS64331B1 (sr) 2015-06-19 2023-08-31 Massachusetts Inst Technology Alkenil supstituisani 2,5-piperazindioni i njihova primena u sastavima za isporuku agensa u organizam ili ćeliju subjekta
HUE067372T2 (hu) 2015-06-29 2024-10-28 Acuitas Therapeutics Inc Lipidek és nanoszemcsés lipid formulázások nukleinsavak beadására
HRP20220156T1 (hr) 2015-09-17 2022-04-15 Modernatx, Inc. Spojevi i pripravci za unutarstaničnu isporuku terapeutskih sredstava
CN108368028B (zh) 2015-10-28 2021-09-03 爱康泰生治疗公司 用于递送核酸的新型脂质和脂质纳米颗粒制剂
US12678515B2 (en) 2015-12-30 2026-07-14 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
ES3030658T3 (en) 2016-03-30 2025-07-01 Intellia Therapeutics Inc Lipid nanoparticle formulations for crispr/cas components
WO2018081318A1 (en) * 2016-10-25 2018-05-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion coronavirus spike proteins and their use
US20180153822A1 (en) 2016-11-10 2018-06-07 Translate Bio, Inc. Process of Preparing mRNA-Loaded Lipid Nanoparticles
CN116549671A (zh) 2016-11-10 2023-08-08 川斯勒佰尔公司 用于递送mrna的改进的基于ice的脂质纳米颗粒制剂
IL310939B2 (en) 2017-02-27 2026-01-01 Translate Bio Inc Large-scale production of therapeutic preparations enriched with mRNA encoding therapeutic peptides
IL268856B2 (en) 2017-02-27 2024-09-01 Translate Bio Inc Methods for purification of messenger rna
ES2899323T3 (es) 2017-02-27 2022-03-10 Translate Bio Inc Métodos de purificación de ARN mensajero
US10780183B2 (en) * 2017-06-19 2020-09-22 Translate Bio, Inc. Messenger RNA therapy for the treatment of Friedreich's ataxia
AU2019271215B2 (en) 2018-05-16 2024-09-12 Translate Bio, Inc. Ribose cationic lipids
CN110974950B (zh) * 2020-03-05 2020-08-07 广州恩宝生物医药科技有限公司 一种用于预防SARS-CoV-2感染的腺病毒载体疫苗
CN110951756B (zh) * 2020-02-23 2020-08-04 广州恩宝生物医药科技有限公司 表达SARS-CoV-2病毒抗原肽的核酸序列及其应用

Also Published As

Publication number Publication date
IL297962A (en) 2023-01-01
WO2021226436A1 (en) 2021-11-11
EP4146265A1 (en) 2023-03-15
US20240342269A1 (en) 2024-10-17
WO2021226436A8 (en) 2022-11-10
AU2021269042A1 (en) 2023-02-02
CA3177940A1 (en) 2021-11-11
JP2023524767A (ja) 2023-06-13

Similar Documents

Publication Publication Date Title
US20240342269A1 (en) Optimized nucleotide sequences encoding sars-cov-2 antigens
US20230364223A1 (en) Coronavirus vaccine
EP4147717A1 (en) Coronavirus vaccine
CN116096407A (zh) 重组人偏肺病毒f蛋白及其用途
CN111499701A (zh) Uspa2蛋白质构建体及其用途
KR20230104068A (ko) 뉴클레오사이드 변형 mRNA를 사용한 범용 인플루엔자 백신
US20260124291A1 (en) Rhinovirus mrna vaccine
US20250319177A1 (en) Rna compositions for delivery of monkeypox antigens and related methods
JP2026062907A (ja) 流行性耳下腺炎ウイルスおよび麻疹ウイルスの免疫原およびそれらの使用
AU2022368453A1 (en) Chimeric betacoronavirus spike polypeptides
CN115594742A (zh) 一种冠状病毒s蛋白变体及其应用
WO2026003578A1 (en) Multisubunit rsv, hmpv and hpiv vaccines and therapeutics
US20230084012A1 (en) Vaccine for use against coronavirus and variants thereof
WO2022204549A1 (en) Optimized nucleotide sequences encoding the extracellular domain of human ace2 protein or a portion thereof
CN116710557A (zh) 编码sars-cov-2抗原的优化核苷酸序列
EP4398884A1 (en) Universal influenza vaccine and methods of use
WO2022171182A1 (zh) 一种治疗或者预防冠状病毒病突变株的疫苗试剂
US20260041759A1 (en) COVID19 mRNA Vaccine
HK40090415A (en) Coronavirus vaccine
WO2025137325A1 (en) Immunization schedules to elicit broadly-neutralizing antibodies against human immmunodeficiency virus (hiv)
HK40066070A (en) An mrna and a novel coronavirus mrna vaccine comprising the same

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601